CureLab Oncology Presents at 2021 ESMO Congress

September 16, 2021 CureLab Oncology Presents at 2021 ESMO Congress The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy BOSTON – September 16, 2021: CureLab Oncology’s a clinical-stage biotech company, is presenting at this year’s European Society for Medical Oncology . Two reports were accepted and are featured as e-posters in the oncology/PRO educational portal for oncologists. The reports describe findings resulting from CureLab’s clinical trials of Elenagen™, an experimental DNA therapy, that are currently underway at N.N. Alexandrov National Cancer Centre of Belarus under the direction of a team led by Deputy Director Professor Sergei Krasny, MD, DSc. The reports are available online: Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer About Elenagen CureLab’s lead investigational compound is code-named Elenagen , an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In animal studies and Phase I/II human trials conducted ex-US, Elenagen has shown promise in reversing tumor grade, changing the tumor microenvironment, and enhancing the anti-cancer effects of chemotherapy. Experimental results indicate a mitigation of chronic inflammation and stimulation of an immune response to the tumor. About CureLab Oncology CureLab Oncology Inc. is a pre-IPO, clinical-stage immuno-oncology biotech company headquartered in the greater Boston area. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelaboncology.com . Media contact: Tim Cox, ZingPR, [email protected] Share Related posts September 3, 2026 Hormone-resistant prostate and breast cancers added to clinical study based on encouraging preliminary results Read more Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.

The release as fetched from its publisher. curelaboncology.com ↗